Amicus Therapeutics Inc (FOLD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Amicus Therapeutics Inc stock (FOLD) is currently trading at $14.43. Amicus Therapeutics Inc PS ratio (Price-to-Sales) is 7.13. Analyst consensus price target for FOLD is $14.50. WallStSmart rates FOLD as Sell.
- FOLD PE ratio analysis and historical PE chart
- FOLD PS ratio (Price-to-Sales) history and trend
- FOLD intrinsic value — DCF, Graham Number, EPV models
- FOLD stock price prediction 2025 2026 2027 2028 2029 2030
- FOLD fair value vs current price
- FOLD insider transactions and insider buying
- Is FOLD undervalued or overvalued?
- Amicus Therapeutics Inc financial analysis — revenue, earnings, cash flow
- FOLD Piotroski F-Score and Altman Z-Score
- FOLD analyst price target and Smart Rating
Amicus Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Amicus Therapeutics Inc (FOLD) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Amicus Therapeutics Inc (FOLD) Key Strengths (3)
104.18% of shares held by major funds and institutions
Strong revenue growth at 23.70% annually
Mid-cap company balancing growth potential with stability
Amicus Therapeutics Inc (FOLD) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Earnings declining -95.50%, profits shrinking
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Very expensive at 16.5x book value
Premium valuation at 7.1x annual revenue
Supporting Valuation Data
Amicus Therapeutics Inc (FOLD) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 1.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth, Market Cap. Growth metrics are encouraging with Revenue Growth at 23.70%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, EPS Growth. Some valuation metrics including PEG Ratio (N/A), Price/Sales (7.13), Price/Book (16.49) suggest expensive pricing. Growth concerns include EPS Growth at -95.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -11.60%, Operating Margin at 8.61%, Profit Margin at -4.28%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -11.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 23.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FOLD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FOLD's Price-to-Sales ratio of 7.13x trades at a deep discount to its historical average of 736.07x (8th percentile). The current valuation is 100% below its historical high of 7069.14x set in Dec 2014, and 103% above its historical low of 3.52x in Jun 2025. Over the past 12 months, the PS ratio has expanded from ~5.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Amicus Therapeutics Inc (FOLD) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Amicus Therapeutics Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 634M with 24% growth year-over-year. The company is currently unprofitable, posting a -4.3% profit margin.
Key Findings
Generating 16M in free cash flow and 16M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -4.3% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 96% YoY while revenue grew 24%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Amicus Therapeutics Inc maintain 24%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Amicus Therapeutics Inc.
Bottom Line
Amicus Therapeutics Inc offers an attractive blend of growth (24% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Amicus Therapeutics Inc(FOLD)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.